INOVA Pharmaceuticals will pull the pin on its proposed acquisition of Juno PC (PD 20 Dec), the Australian Competition and Consumer Commission (ACCC) revealed.
The ACCC flagged concerns the deal could have restricted competition in the prescription weight-loss medication category, with Juno PC having developed a new patient-protected phentermine-based drug with the potential to rival iNova's brands.
The ACCC has discontinued its review of the deal as a result.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jan 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jan 20
